26 February 2021 in Clinical pharmacy
Chlorhexidine is an effective cationic antiseptic and disinfectant that has been used in medical practice for decades. It is generally recommended to use different concentrations of aqueous or alcoholic solutions of chlorhexidine for different therapeutic purposes. Objective. To determine the proportions of different chlorhexidine concentrations in medicines purchased by state and municipal organizations and to identify possible issue of chlorhexidine formulations utilization in the suboptimal or insufficient concentrations. Results. The vast majority of the chlorhexidine-containing medicines found in the State Register of Medicines of Ukraine are 0.05% solutions for external use, 0.05% gels for dental and urological use and vaginal suppositories (pessaries) with 16 mg of chlorhexidine in one dose. While the most common representatives of chlorhexidine-containing medicines abroad are solutions with a concentration of 4% and 2%, as well as mouthwashes with a concentration of 0.12%. The highest share - 96% - among the procurements of chlorhexidine-containing medicines by state and municipal organizations is 0.05% aqueous solution for external use. Instructions for medical use of 0.05% aqueous chlorhexidine solution for external use contain indications that are not supported by international documents: WHO Model List of Essential Medicines and British National Formulary. Conclusions. The obtained results suggest probable cases of irrational use of chlorhexidine medicines in medical practice in Ukraine. The consequences of such cases are not limited to the failure to achieve therapeutic goals or to the development of nosocomial infection, but includes also the selection of chlorhexidine-resistant strains of microorganisms. Key words: chlorhexidine; assortment analysis; medicinal procurements study; suboptimal concentration; rational pharmacotherapy
31 March 2025 in Medical Science of Ukraine (MSU)
Background. Psoriasis is a chronic autoimmune disease that significantly impairs the quality of life of patients and is characterized by epidermal hyperproliferation, inflammatory infiltration, and disrupted keratinization processes. Despite the wide range of existing therapeutic approaches, many drugs are associated with adverse effects that limit their long-term use. This substantiates the need for developing new topical agents with high efficacy and a favorable safety profile. Aim: To investigate morphological changes in the skin and assess the efficacy of novel topical formulations containing refined Naftalan oil (RNO) in cream and ointment forms in a mouse model of experimentally induced psoriatic skin lesions. Materials and methods. The study was conducted on adult BALB/c mice of both sexes (n=34). Psoriatic lesions were induced by daily application of 5% imiquimod to a depilated area of the back skin over 9 days. After the development of pathological changes, the following test samples were applied: a cream containing 10% refined Naftalan oil and an ointment with 10% refined Naftalan oil combined with 3% salicylic acid. A cream containing 1% hydrocortisone butyrate was used as a reference preparation. Therapeutic efficacy was evaluated by monitoring the dynamics of the mPASI index over 21 days. Results. The test sample of cream containing 10% refined Naftalan oil demonstrated a moderate antipsoriatic effect, manifested by reductions in erythema, infiltration, and desquamation. The ointment containing 10% refined Naftalan oil and 3% salicylic acid exhibited a more pronounced therapeutic effect due to the synergistic action of its components, which includes the keratolytic action of salicylic acid and enhanced penetration of active substances into deeper skin layers. The reference preparation showed lower efficacy compared to the combined test sample. Conclusion. Refined Naftalan oil demonstrated a favorable safety profile for topical use and the ability to enhance the penetration of active pharmaceutical ingredients into deeper layers of the skin. The combination of refined Naftalan oil with salicylic acid provides a synergistic therapeutic effect, confirmed by macro- and microscopic evaluations of skin condition, which opens up prospects for the use of these substances in dermatological preparations for psoriasis treatment.
28 February 2025 in ScienceRise: Pharmaceutical Science
The aim of this work was to evaluate the combination of purified naftalan oil (PNO) with salicylic acid (SA) for topical application as a potential effective antipsoriatic ointment and to study the mechanism of its action using specific in vitro cell models. Material and methods. The effectiveness and safety of the following dosage forms were studied: ointment with 10 % PNO and 3 % SA (PNO-SA), cream with 0.064 % betamethasone dipropionate (BD), and ointment with 3 % SA. Cell viability of original HaCaT human keratinocytes and modified HaCaT/P was determined by colorimetric methods, namely by crystal violet staining or the MTT test method. The level of apoptosis of cells was evaluated by flow cytometry. Production of pro-inflammatory cytokines IL-8 and IL-1β was measured by the ELISA method. Results. It was shown that the sensitivity of cells with a psoriasis-like phenotype (HaCaT/P) to PNO increases statistically significantly compared to control cells, which was confirmed by both the cell viability and the MTT test. to obtain a result with inhibition of cells with psoriasis-like characteristics, HaCaT/P requires a smaller concentration of the drug compared to a similar effect on conditionally normal cells – HaCaT. This may indicate the relative safety of the proposed medicinal product (combination) in parallel with the conditions of its effectiveness concerning pathologically changed cells. The results of flow cytometry showed that the new PNO-SA complex causes a statistically significant increase in the percentage of cells in all phases of apoptosis compared to control cells. Finally, a statistically significant decrease in the production of IL-8 by cells with psoriasis-like characteristics – the HaCaT/P line was shown in the presence of the PNO-SA combination compared with control cells. In addition, there was a significant decrease in the level of IL-8 production in cells in the presence of the combination compared to SA and the comparator BD. However, in terms of its effect on IL-1β production, the PNO-SA combination proved to be inactive. Conclusion. Our proposed combination (PNO-SA), which suppresses pro-inflammatory IL-8 by more than 2 times (by 67.4 %) compared to the control, is a promising potential option for local treatment of psoriatic lesions. We speculate about the future demand of this combination in the clinical setting because along with high efficiency (in terms of viability indicators – the number of living cells, the level of apoptosis) towards pathologically changed keratinocytes, it shows a low toxicity profile towards normal healthy keratinocytes